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Background: Structural information for substrate binding to human steroidogenic cytochrome P450 17A1 (CYP17A1) is
unavailable.
Results: Within a common overall orientation, different steroids adopt subtly different positions.
Conclusion: Steric and hydrogen-bonding modulation of lateral/vertical orientation controls CYP17A1-mediated steroid oxidation.
Significance: Understanding the CYP17A1 mechanism provides opportunities for better targeted drug design.
The human cytochrome P450 17A1 (CYP17A1) enzyme operates at a key juncture of human steroidogenesis, controlling the
levels of mineralocorticoids influencing blood pressure, glucocorticoids involved in immune and stress responses, and androgens and estrogens involved in development and homeostasis of
reproductive tissues. Understanding CYP17A1 multifunctional
biochemistry is thus integral to treating prostate and breast cancer, subfertility, blood pressure, and other diseases. CYP17A1
structures with all four physiologically relevant steroid substrates suggest answers to four fundamental aspects of
CYP17A1 function. First, all substrates bind in a similar overall
orientation, rising ⬃60° with respect to the heme. Second, both
hydroxylase substrates pregnenolone and progesterone hydrogen bond to Asn202 in orientations consistent with production
of 17␣-hydroxy major metabolites, but functional and structural evidence for an A105L mutation suggests that a minor conformation may yield the minor 16␣-hydroxyprogesterone
metabolite. Third, substrate specificity of the subsequent 17,20lyase reaction may be explained by variation in substrate height
above the heme. Although 17␣-hydroxyprogesterone is only
observed farther from the catalytic iron, 17␣-hydroxypregnenolone is also observed closer to the heme. In conjunction
with spectroscopic evidence, this suggests that only 17␣-hydroxypregnenolone approaches and interacts with the proximal
oxygen of the catalytic iron-peroxy intermediate, yielding efficient production of dehydroepiandrosterone as the key intermediate in human testosterone and estrogen synthesis. Fourth,
differential positioning of 17␣-hydroxypregnenolone offers a
mechanism whereby allosteric binding of cytochrome b5 might
selectively enhance the lyase reaction. In aggregate, these structures provide a structural basis for understanding multiple key
reactions at the heart of human steroidogenesis.
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The cytochrome P450 superfamily of heme monooxygenases
performs diverse physiological functions, ranging from drug
and xenobiotic metabolism to hormone and vitamin biosynthesis. The human cytochrome P450 (P450)3 enzyme 17A1
(CYP17A1) functions specifically at a critical juncture in
human steroidogenesis (1). Its initial substrates are also substrates for mineralocorticoid biosynthesis by other enzymes.
CYP17A1 catalysis leads to either steroid precursors of glucocorticoids like cortisol that regulate immune response or
androgens like testosterone that drive the development and
maintenance of male characteristics or are converted to estrogens in females (2). In later life, however, androgens drive the
development of prostate cancer, the cancer of highest incidence
and the second leading cause of cancer deaths in American
men, whereas estrogens are a long recognized driver of hormone-responsive breast cancer (3). Thus this enzyme has garnered substantial interest as a relatively new drug target, validated by successful use of the CYP17A1 inhibitor abiraterone in
men with castration-resistant prostate cancer (4 – 6) and its
current evaluation in breast cancer patients.
Abiraterone acetate, the Food and Drug Administration-approved prodrug form of this CYP17A1 inhibitor, improves
overall survival in men with metastatic castration-resistant
prostate cancer, including patients for whom the disease has
progressed following chemotherapy, with compounds such as
docetaxel and the androgen receptor blocker enzalutamide (5,
7). Abiraterone binds with high affinity to the CYP17A1 active
site heme iron (8) that is essential for catalysis, which effectively
and systemically prevents androgen production. However, by
doing so, this inhibitor also increases the pool of precursors for
mineralocorticoid production and halts CYP17A1-mediated
production of glucocorticoids, which occurs in the same active
site and also requires the heme iron. The resulting steroid
imbalances in patients treated with abiraterone can frequently
lead to hypertension, hypokalemia, and adrenocortical insufficiency, which must then be monitored and treated with additional drugs (9). Furthermore, there is some evidence that the
increase in mineralocorticoids associated with complete inhi3

The abbreviations used are: P450, cytochrome P450; b5, cytochrome b5;
RMSD, root mean square deviation.

VOLUME 289 • NUMBER 47 • NOVEMBER 21, 2014

CYP17A1/Steroid Substrate Structures
bition of CYP17A1 may facilitate the flow of androgen precursors through a “backdoor” androgen biosynthesis pathway (10),
proposed to provide a possible escape route that could permit
cancer progression. Selective inhibition of the CYP17A1-mediated androgen biosynthesis proven to increase overall survival,
whereas sparing CYP17A1-mediated glucocorticoid biosynthesis to prevent corticosteroid imbalances would ameliorate
both of these clinically relevant issues for prostate cancer
patients. CYP17A1 impairment has also been associated with
Cushing’s syndrome (11), some forms of congenital adrenal
hyperplasia (12), and polycystic ovary syndrome (13–15). Substantial potential for improving prostate cancer treatment and
therapies for these other diseases thus lies in an improved
understanding of the mechanisms whereby CYP17A1 performs
catalysis.
In general, CYP17A1 hydroxylates the mineralocorticoid
precursor steroids pregnenolone and progesterone to yield 17␣hydroxypregnenolone and 17␣-hydroxyprogesterone, respectively (see Fig. 1). These resulting C17-hydroxylated steroids can
serve as substrates for glucocorticoid biosynthesis or for the subsequent CYP17A1-mediated 17,20-lyase reaction to yield the
androgens dehydroepiandrosterone or androstenedione (see
Fig. 1). Functional variations on this general pathway for different substrates provide clues to key protein/small molecule
interactions that direct catalysis.
First, although human CYP17A1 hydroxylates pregnenolone
(a ⌬5,3-ol steroid) only at carbon 17, progesterone (the corresponding ⌬4,3-keto steroid) is hydroxylated at C17 as the major
product, but also at C16 to generate an additional minor product (see Fig. 1) (14, 16). It is known that in other species
CYP17A1 with Leu at position 105 generates much less 16␣hydroxyprogesterone (14) and that an A105L mutation in the
human CYP17A1 enzyme decreases progesterone 16␣-hydroxylation and increases its 17␣-hydroxylation (17). Suggested to somehow alter substrate position in the CYP17A1
active site or alter protein flexibility, the structural basis for the
effects of the A105L mutation on substrate and regioselectivity
of hydroxylation have not been elucidated experimentally.
Second, CYP17A1 also performs a carbon-carbon bond
cleavage, which is unusual for cytochrome P450 enzymes (18).
For human CYP17A1, this 17,20-lyase reaction proceeds far
less efficiently for the ⌬4,3-keto 17␣-hydroxyprogesterone substrate than for its counterpart, the ⌬5,3-ol 17␣-hydroxypregnenolone (see Fig. 1). As a result, the ⌬5,3-ol 17␣-hydroxypregnenolone 17,20-lyase product dehydroepiandrosterone (see
Fig. 1) is the physiologically relevant intermediate in the formation of all human androgens and estrogens (19). Although
hydroxylation is well established to occur by the Groves hydrogen abstraction/oxygen rebound mechanism mediated by an
Fe(IV)-oxo catalytic intermediate called Compound I (20, 21)
(see Fig. 1), a mechanism for cleavage of the bond between
carbons 17 and 20 has been an ongoing debate in the literature.
Recent data, however, favors a ferric peroxy anion intermediate
(see Fig. 1) (22, 23), and spectroscopic evidence has suggested
that the two 17␣-hydroxy steroids might interact differentially
with this peroxy intermediate (24).
Third, although the presence of cytochrome b5 has relatively
little effect on the hydroxylation reactions, the presence of this
NOVEMBER 21, 2014 • VOLUME 289 • NUMBER 47

small heme protein (25–28) substantially and selectively facilitates the 17,20-lyase reaction. Compartmentalization of b5 and
developmental changes in b5 levels control the tissue specificity
and timing of androgen production in humans. Individuals with
nonfunctional b5 are unable to perform the lyase reaction and
produce sex steroids, although the hydroxylase reaction
required for glucocorticoid synthesis is operational (29, 30).
Facilitation of the lyase reaction by b5 occurs without electron
delivery (25). Thus it has been suggested that b5 might selectively stabilize the intermediate in the lyase reaction or cause
substrates to assume orientations in the CYP17A1 active site
more favorable for the lyase chemistry, but the mechanism
remains unresolved (31).
The structural basis for each of these effects— hydroxylase
substrate regioselectivity, lyase reaction selectivity for the ⌬4,3keto versus ⌬5,3-ol 17-hydroxylated substrate, and cytochrome
b5 facilitation of the lyase versus hydroxylase reaction—is
unknown. Homology models and docking studies have suggested that substrates were likely to orient essentially parallel to
the plane of the heme (32) and proposed a “bi-lobed” active site
to carry out the separate hydroxylase and lyase reactions (33–
36). The only known structures of CYP17A1, in the presence of
the steroidal inhibitors abiraterone or TOK-001, were published recently (8). These steroidal inhibitors both orient more
nearly perpendicular to the heme, evoking the prediction of a
similar binding mode for substrates (8), but the actual binding
of CYP17A1 substrates is unknown.
To probe the binding orientations of the physiologically relevant substrates and the structural basis of CYP17A1 function,
a series of experimental x-ray structures were generated for
CYP17A1 in complexes with both hydroxylase and both lyase
substrates with the mutation A105L. Comparisons among
these structures identify steric and hydrogen bonding interactions between CYP17A1 and distal portions of the substrate
that play key roles in modulating spatial relationships between
sites of metabolism on the opposite end of substrates and the
catalytic heme iron. A steric rationale is provided for hydroxylase regioselectivity, whereas differences observed for hydrogen
bonding and substrate positioning may form the basis for substrate selectivity of the lyase reaction. This new information
informs a working hypothesis for how cytochrome b5 might
selectively facilitate the lyase reaction.

EXPERIMENTAL PROCEDURES
Mutagenesis—The CYP17A1 gene in the pCWori⫹ vector
has an N-terminal truncation of residues 1–19, a slight modification of the new N terminus, and a C-terminal 4⫻ histidine
tag, as described (8). The A105L mutation was incorporated
using the QuikChange Lightning site-directed mutagenesis kit
(Agilent).
Expression—The resulting pCW17A1⌬19H plasmid containing either the wild type or A105L sequence was transformed into Escherichia coli JM109 cells by heat shock at 42 °C,
spread on lysogeny broth agarose plates containing 50 g/ml
ampicillin and incubated overnight at 37 °C. To select for the
pCWori⫹ vector, all expression media were supplemented
with 50 g/ml ampicillin. Lysogeny broth (5 ml) was inoculated
with a single colony from the aforementioned plate and incuJOURNAL OF BIOLOGICAL CHEMISTRY
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bated at 37 °C with shaking at 250 rpm for 6 h. Overnight cultures (200 ml of lysogeny broth) were inoculated with 50 l of
the initial culture and incubated at 37 °C for 18 h with 250 rpm
shaking. Terrific Broth (1 liter/2.8-liter Fernbach flask) was
inoculated with 10 ml of the overnight culture. This culture was
grown at 37 °C with shaking at 250 rpm until reaching an optical density of 0.5 at 600 nm. Overexpression was then induced
by the addition of isopropyl ␤-D-1-thiogalactopyranoside (0.5
mM). The heme precursor ␦-aminolevulinic acid was added to
0.61 mM. Cultures were grown at 28 °C with shaking at 140 rpm
for an additional 72 h. The cells were then collected by centrifugation at 6300 ⫻ g for 10 min. Cells were resuspended in 50
mM Tris-HCl, pH 7.4, 20% (v/v) glycerol, and 300 mM NaCl and
stored at ⫺80 °C until purification.
Purification—Cells were thawed and lysed by sonication (six
times for 30 s at 1-min intervals on ice). The resulting lysate was
centrifuged at 9900 ⫻ g for 15 min. Membrane proteins were
extracted by stirring this lysate in the presence 2% (v/v) Emulgen 913 (Desert Biologicals) for 90 min, followed by ultracentrifugation (100,000 ⫻ g for 1 h). The resulting supernatant was
loaded on nickel-nitrilotriacetic acid-agarose resin (Qiagen)
pre-equilibrated with Ni buffer (50 mM Tris-HCl, pH 7.4, 20%
(v/v) glycerol, 300 mM NaCl, and 0.2% (v/v) Emulgen 913). The
resin was subsequently washed with 2 column volumes of Ni
buffer, 6 column volumes of Ni buffer supplemented with 100
mM glycine, and eluted using 4 column volumes of Ni buffer
supplemented with 100 mM glycine and 80 mM histidine. Elution fractions were pooled based on absorbance of the heme
Soret peak, diluted 4.2-fold in CM buffer (50 mM Tris-HCl, pH
7.4, 20% (v/v) glycerol, and 100 mM glycine), supplemented with
0.2% (v/v) Emulgen 913, and loaded onto a 5-ml carboxymethyl-Sepharose fast-flow column (GE Healthcare) previously
equilibrated with CM buffer. The column was washed with 10
column volumes of CM buffer and eluted with CM buffer supplemented with 500 mM NaCl. Fractions were pooled based on
the heme Soret absorbance and concentrated to ⬃1 ml. Concentrated protein was injected onto a Superdex 200 gel filtration column (GE Healthcare) pre-equilibrated with buffer containing 50 mM Tris-HCl, pH 7.4, 20% (v/v) glycerol, 100 mM
glycine, and 500 mM NaCl. The major peak with absorbance for
the heme was collected and concentrated. All purification was
performed at 4 °C. CYP17A1 A105L protein generated for crystallization studies was purified with 50 M of one of the ligands
present in all purification buffers.
Protein Crystallization, Data Collection, and Structure
Determination—CYP17A1 A105L was crystallized by hanging
drop vapor diffusion. Purified protein (⬃29 mg/ml) containing
either 50 M of one of the substrates or 10 M abiraterone and
0.5% (v/v) Emulgen 913 was mixed 1:1 to form 2-l drops that
were then equilibrated against precipitant solution at 20 °C.
The precipitant solution used to crystallize CYP17A1 A105L
with progesterone, pregnenolone, 17␣-hydroxypregnenolone,
and abiraterone consisted of 100 mM Tris-HCl, pH 8.5, 25%
(v/v) PEG 4000 (Hampton Research), 150 mM magnesium chloride hexahydrate, and 4 – 6% (v/v) glycerol. The precipitant
solution used to crystallize CYP17A1 A105L with 17␣-hydroxyprogesterone contained 175 mM Tris-HCl, pH 8.5, 30%
(v/v) PEG 3350 (Hampton Research), 250 mM lithium sulfate,
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and 3% (v/v) glycerol. Crystals were cryoprotected in a 7:3 mixture of mother liquor and 80% (v/v) glycerol and flash cooled in
liquid nitrogen. Diffraction data were collected on Beamlines
14-1 and 12-2 of the Stanford Synchrotron Radiation Lightsource and processed using XDS (37). Data collection and
refinement statistics and deposition codes in the Protein Data
Bank are given in Table 1. Structures were solved by molecular
replacement using Phaser (38) and the structure of wild type
CYP17A1 (Protein Data Bank codes 3RUK or 3SWZ (8)) as a
search model using data to the respective resolution cutoff for
the different structures (2.5–3.0 Å), yielding log likelihoods of
9,094 –13,090. Model building and refinement were performed
iteratively with Coot (39) and PHENIX (40), respectively, using
data to a cutoff of ⬍I/(I)⬎ of 1.5 or higher in the outer shell.
Hydrogens were modeled in the riding positions for protein and
substrates. Reference model restraints were incorporated only
for the 3.0 Å 17␣-hydroxypregnenolone data set, to avoid overfitting. After the protein structures were essentially completed,
ligands were added. The ligand omit 2Fo ⫺ Fc maps shown were
calculated in PHENIX. Ligand models were obtained from the
Hetero-compound Information Center at Uppsala (HIC-Up)
or constructed using the PRODRG2 server. Superpositions
between CYP17A1 molecules were generated using the secondary structure matching algorithm in COOT (39). Superposition
between P450cam and CYP17A1 was generated by the same
process, then optimized using least squares fit for the hemes,
also in COOT (39). Probe-occupied active site volumes were
generated using VOIDOO (41) (probe radius ⫽ 1.4 Å; grid
spacing ⫽ 0.33). The figures were prepared in PyMOL (42).
Progesterone Hydroxylation Assays—Hydroxylation of progesterone (0 –70 or 200 M) by CYP17A1 was determined after
HPLC separation by UV absorbance detection as described (8).
A modification to this assay was the use of human NADPHcytochrome P450 reductase bearing an N-terminal truncation
(43), in addition to a K59Q mutation that prevents proteolysis.
Metabolites 17␣-hydroxyprogesterone, 21-hydroxyprogesterone, and 16␣-hydroxyprogesterone were detected at 248 nm
with retention times of ⬃5.5, ⬃4.1, and ⬃2.2 min, respectively.
Pregnenolone Hydroxylation and 17,20-Lyase Assays—
CYP17A1 (50 pmol) was incubated at 4 °C with the human P450
oxidoreductase described above and rat cytochrome b5 in
either a 1:4:4 ratio (for 17,20-lyase reactions) or 1:4:0 ratio (for
pregnenolone hydroxylation reactions) for 20 min. This reconstituted system was added to buffer (50 mM Tris-HCl, pH 7.4,
and 5 mM magnesium chloride) containing substrate (0 –7 M
pregnenolone for hydroxylation or 0 –20 M 17␣-hydroxypregnenolone for 17,20-lyase) to a total volume of 480 l. The reactions were carried out at 37 °C and were initiated by the addition of NADPH (20 l of 25 mM). After 10 min, reactions were
quenched by the addition of 20% (w/v) trichloroacetic acid (300
l) containing 8.66 g/ml estriol as an internal standard. Both
samples and standards (650 l) were loaded onto SPE columns
(HLB cartridge, 1 ml, 30 mg of packing) pre-equilibrated with
2⫻ 1 ml of methanol, followed by 2⫻ 1 ml of H2O. Following
sample loading, the columns were washed with 1 ml of H2O and
steroids eluted using 4⫻ 1 ml of 1:2 dichloromethane:methanol. Eluent was dried and resuspended in 100 l of derivitizing
reagent prepared as a 500:4:2 (v/w/w) mixture of N-methyl-NVOLUME 289 • NUMBER 47 • NOVEMBER 21, 2014
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FIGURE 1. Summary of human cytochrome P450 17A1 reactions. Progesterone is hydroxylated at either C16 (minor, red) or C17 (major, blue) via Groves
hydrogen abstraction and rebound mediated by the typical P450 iron (IV)-oxo intermediate (21). The resulting 17␣-hydroxyprogesterone metabolite undergoes the 17,20-lyase reaction to androstenedione (pink) with very low efficiency. Conversely, pregnenolone is hydroxylated only at C17 (blue). The resulting
17␣-hydroxypregnenolone metabolite efficiently undergoes the 17,20-lyase reaction to form the 19-carbon androgen dehydroepiandrosterone (pink), proposed to occur via an iron-peroxy intermediate (22). The latter reaction is facilitated as much as 10-fold by the presence of cytochrome b5 (25). CYP17A1
hydroxylase substrates progesterone and pregnenolone are also converted to mineralocorticoids and 17␣-hydroxy products to glucocorticoids, largely by
other cytochrome P450 enzymes.

absorbance as described previously (45) except that 100 nM
protein was in 50 mM Tris-HCl, pH 7.4, 20% (v/v) glycerol,
and 100 mM glycine, and the cuvettes had path lengths of 5
cm. Changes in absorbance were fit to the tight binding
equation using Prism (GraphPad Software) to determine the
dissociation constants.

RESULTS

FIGURE 2. The overall structure of CYP17A1 A105L molecules A/B (shown
in rainbow colors) and C/D (gray) have small variations in the backbone
structure on one face of the enzyme, including the N terminus, the residues between the F and G helices, and a small portion of the adjacent ␤1
sheet. Dashed line, HI turn residues not modeled because of weak density.

(trimethylsilyl)-trifluoroacetamide/ammonium iodide/dithiothreitol and heated to 60 °C for 40 min. Derivatized samples
were injected onto GC/MS (3-l injection for lyase samples and
5-l injections for hydroxylase samples) and analyzed in
selected ion monitoring mode using instrument parameters as
described (44) except that the column was Agilent DB-5MS,
15 ⫻ 0.25-mm inner diameter with 0.25-micron film. Silylated
derivatives of products 17␣-hydroxypregnenolone (retention
time ⬃16.5 min; m/z ⫽ 548) and dehydroepiandrosterone
(retention time, ⬃7.9 min; m/z ⫽ 432) were quantified based on
their molecular ion with respect to that of silylated estriol internal standard (retention time ⬃15.7 min; m/z ⫽ 504).
Ligand Binding Assays—Ligands were titrated into CYP17A1
protein and binding monitored by changes in UV-visible
NOVEMBER 21, 2014 • VOLUME 289 • NUMBER 47

Characterization of CYP17A1 Ligand Binding and Substrate
Metabolism—To compare the interactions of CYP17A1 with its
various substrates and products, upon A105L mutation, and
with structural findings, both dissociation constants and
steady-state kinetic parameters were measured (Table 2).
CYP17A1 affinities for steroid substrates and products were
evaluated by monitoring the spectral shift associated with displacement of an active site water from the heme iron that
occurs as ligands bind adjacent to the heme. Steady-state
kinetic parameters were determined for all three substrates
with appreciable product formation (progesterone and pregnenolone 17␣-hydroxylation reactions and the 17␣-hydroxypregnenolone 17,20-lyase reaction).
Progesterone binds more tightly to wild type CYP17A1 than
either its major (17␣-) or minor (16␣-) hydroxylation products,
with the 16␣-hydroxyl conferring a notable ⬎80-fold decrease
in affinity (Table 2). Similarly, pregnenolone binds wild type
CYP17A1 more tightly than its 17␣-hydroxylated product.
Higher affinities are observed for all pregnenolone-based
(⌬5,3-ol) ligands than for the corresponding progesterone
(⌬4,3-keto) compounds. The effect of the A105L mutation is to
increase progesterone affinity at least 2-fold but has little effect
on the already lower affinity for either progesterone hydroxylation product. Pregenenolone binds with such high affinity to
both wild type and A105L that any changes in affinity caused by
mutation are not apparent, but the decrease in affinity that the
JOURNAL OF BIOLOGICAL CHEMISTRY

32955

CYP17A1/Steroid Substrate Structures
TABLE 1
Statistics for x-ray data collection and refinement
CYP17A1 A105L
abiraterone
Protein Data Bank code
Data collection
Beamline
Space group
Cell dimensions:
a, b, c, (Å)
Molecules/a.u.
Resolution (Å)a
Total reflectionsa
Unique reflectionsa
Redundancya
Rpima
⬍I/(I)⬎a
Completeness (%)a
Refinement
Resolution (Å)
No. reflections
R/Rfree (%)
Ramachandran (%)
Favored
Allowed
Outliers
Wilson B factor
No. atoms/B factors
Protein
Ligand
Heme
Water
RMSD bond (Å)
RMSD angle (°)
Coordinate error (maximumlikelihood based)
Key bond distances
and anglesb
N/ON202-O3 (Å)
⬔C3-O3-N/ON202 (°)
C16-iron (Å)
C17-iron (Å)
C20-iron (Å)
a
b

CYP17A1 A105L
pregnenolone

CYP17A1 A105L
progesterone

CYP17A1 A105L
CYP17A1 A105L
17␣-hydroxy-progesterone 17␣-hydroxy-pregnenolone

4NKV

4NKW

4NKX

4NKY

4NKZ

SSRL 12-2
P212121
90.7, 153.3, 167.7

SSRL 14-1
P212121
86.1, 152.6, 173.8

SSRL 12-2
P212121
85.9, 153.0, 173.2

SSRL 12-2
P212121
91.3, 151.8, 168.0

SSRL 12-2
P212121
85.8, 151.1, 170.3

4
39.31-2.65 (2.79-2.65)
450,626 (62,230)
68,380 (9,523)
6.6 (6.5)
0.044 (0.556)
6.8 (1.5)
99.3 (96.1)

4
39.11-2.50 (2.63-2.50)
557,941 (64,186)
79,365 (11,000)
7.0 (5.8)
0.060 (0.717)
11.0 (2.1)
99.3 (95.6)

4
39.13-2.79 (2.94-2.79)
380,303 (52,751)
56,987 (7,891)
6.7 (6.7)
0.074 (0.579)
9.7 (1.5)
99.2 (95.5)

4
39.15-2.55 (2.69-2.55)
511,008 (71,923)
76,008 (10,667)
6.7 (6.7)
0.060 (0.666)
12.3 (1.5)
99.1 (96.3)

4
38.70-3.00 (3.17-3.00)
287,854 (36,646)
44,496 (6,106)
6.5 (6.0)
0.080 (0.650)
8.9 (1.5)
98.9 (94.3)

38.59-2.65
68,166
19.1/24.3

39.11-2.50
79,236
18.9/24.5

39.13-2.80
56,820
18.4/25.7

39.15-2.55
75,825
17.8/24.4

38.70-3.00
43,862
19.1/26.1

96.44
3.45
0.11
61.4

95.50
4.39
0.11
52.8

95.63
4.26
0.11
56.9

96.46
3.54
0
51.4

96.78
3.06
0.16
68.6

14913/71.6
104/36.7
172/50.5
139/50.4
0.011
1.2
0.41

14852/71.8
92/61.1
172/50.4
87/52.6
0.008
1.2
0.34

14925/59.3
92/46.3
172/41.9
46/37.4
0.008
1.1
0.41

14832/56.8
96/52.3
172/44.1
161/44.5
0.007
1.2
0.33

14806/80.1
96/65.7
172/63.8
8/65.9
0.010
1.3
0.39

2.7 ⫾ 0.1
102 ⫾ 3
5.9 ⫾ 0.2
5.7 ⫾ 0.1
4.6 ⫾ 0.2

2.8 ⫾ 0.1
121 ⫾ 5
4.9 ⫾ 0.2
4.8 ⫾ 0.1
4.6 ⫾ 0.1

2.7 ⫾ 0.3
121 ⫾ 7
4.8 ⫾ 0.2
4.8 ⫾ 0.1
4.6 ⫾ 0.1

2.9 ⫾ 0.05
137 ⫾ 4
4.7 ⫾ 0.1
5.0 ⫾ 0.1
4.6 ⫾ 0.2

2.8, 2.5, 3.8, 3.0
144, 132, 135, 136
5.1, 5.1, 4.6, 4.7
4.8, 4.8, 4.4, 4.6
4.6, 4.6, 4.4, 4.4

Statistics corresponding to the highest resolution shell are in parentheses.
Atomic elements refer to steroid or heme (iron) atoms unless an amino acid designation is provided as a subscript.

17␣-hydroxy substituent confers on pregnenolone is offset by
the A105L mutation.
Significant catalytic differences are also observed for different substrates and upon mutation (Table 2). The wild type
CYP17A1 17-hydroxylates pregnenolone with a Km that is
10-fold lower than for progesterone 17-hydroxylation, consistent with the rank order of the dissociation constants. Although
the kcat is ⬃3-fold lower for pregnenolone 17-hydroxylation
than for progesterone 17-hydroxylation, the overall catalytic
efficiency (kcat/Km) is still 4.4-fold higher for pregnenolone
17-hydroxylation. The A105L mutation does not alter kcat for
the 17-hydroxylation of either substrate but does substantially
decrease the Km for both reactions, consistent with general
increases observed in the dissociation constants reported above.
Although pregnenolone is only hydroxylated at C17,
human CYP17A1 is reported to also convert progesterone to
the minor 16␣-hydroxylated metabolite (Fig. 1), which can
compose 10 –30% of total hydroxylated metabolites depending on the system under study (17, 46). For wild type
CYP17A1 in the current purified enzyme system at saturating
progesterone concentrations, 16␣-hydroxyprogesterone comprised 12% of the total progesterone hydroxylase activity, with
17␣-hydroxyprogesterone accounting for the remainder. The
A105L mutation was reported to increase 17-hydroxylation
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and decrease 16-hydroxylation in a cell-based system (17). In
agreement, under the same conditions used to evaluate the wild
type enzyme herein, CYP17A1 A105L yielded only ⬃5% of the
total hydroxy metabolites as the 16␣-hydroxyprogesterone
minor product, with 95% being the 17␣-hydroxyprogesterone
metabolite. Thus these functional results agree that the A105L
mutation increases the affinity of CYP17A1 for progesterone
and that it does so by preferentially orienting progesterone for
hydrogen abstraction at C17 over C16.
Human CYP17A1 has also been noted to produce very small
amounts of 21-hydroxyprogesterone, also called 11-deoxycorticosterone, which is increased with the A105L mutation (46).
Although the current purified system yielded no detectable
21-hydroxyprogesterone at the highest substrate concentrations used for determining steady-state kinetic parameters (70
M), at much higher progesterone concentrations (200 M),
trace amounts of 21-hydroxyprogesterone were inconsistently
detected for the A105L mutant but never for the wild type
enzyme. Thus the A105L mutation appears to slightly increase
the production of 21-hydroxyprogesterone.
In contrast to hydroxylation reactions, where the A105L
mutation altered only the Km, in the 17,20-lyase reaction the
mutation had no effect on the Km. Instead the mutation
resulted in a 5-fold increase in kcat, suggesting that the A105L
VOLUME 289 • NUMBER 47 • NOVEMBER 21, 2014
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TABLE 2
Substrate binding and steady-state kinetic parameters for the metabolism of physiologically relevant steroid substrates by CYP17A1 wild
type and the A105L mutant
Wild type

A105L

Steroid substrate and product
Kd values (nM)
Pregnenolone
Progesterone
17␣-Hydroxypregnenolone
17␣-Hydroxyprogesterone
16␣-Hydroxyprogesterone

⬍100 (8)
230 ⫾ 14 (8)
210 ⫾ 7
330 ⫾ 22
8700 ⫾ 600

⬍100
⬍100
⬍100
390 ⫾ 90
8900 ⫾ 600

Progesterone 17␣-hydroxylation
kinetics
kcat (min⫺1)
Km (M)

1.01 ⫾ 0.05
10.5 ⫾ 1.7

1.16 ⫾ 0.01
1.96 ⫾ 0.097

Pregnenolone 17␣-hydroxylation
kinetics
kcat (min⫺1)
Km (M)

0.39 ⫾ 0.03
0.93 ⫾ 0.24

0.39 ⫾ 0.03
0.38 ⫾ 0.09

17␣-Hydroxypregnenolone
17,20-lyase kinetics
kcat (min⫺1)
Km (M)

0.24 ⫾ 0.02
1.2 ⫾ 0.3

1.2 ⫾ 0.08
1.2 ⫾ 0.3

mutation contributes to interactions that more readily permit
the lyase reaction while having little affect on affinity.
Global Overview of CYP17A1 A105L Structures—Introduction of the A105L mutation increased general CYP17A1 stability during purification (and likely during expression as well), as
evaluated by overall protein yield. This consistently higher
yield, perhaps in combination with an increased affinity for at
least two of the steroid substrates, facilitated determination of a
series of CYP17A1 A105L liganded x-ray structures for side by
side comparison. All crystallized in the same space group with
the same packing. Comparison of the four molecules composing the asymmetric unit for one substrate complex with any of
the other substrate complexes or for a complex with the inhibitor abiraterone reveals they are all very similar to each other
(average root mean square deviation (RMSD) over all C␣ of
0.42 ⫾ 0.10) and to previous structures of wild type CYP17A1
bound to abiraterone and another steroidal inhibitor (average
RMSD over all C␣ 0.41 ⫾ 0.10) (8). However, for all CYP17A1
structures to date, two of the four molecules in the asymmetric
unit (molecules A and B) differ slightly from the other two
(molecules C and D), resulting in a higher C␣ RMSD of 1.29 ⫾
0.06. Structural differences between these two conformations
are observed at the backbone level for the N terminus, a loop
between ␤1 strands, and the F-G region (Fig. 2). These regions
all lie on one face of the molecule that was proposed to be
involved in membrane binding. As is true for almost all membrane P450 structures, this surface also constitutes a packing
interaction with neighboring molecules in the crystalline lattice
and is known to be relatively flexible. Therefore it is difficult to
determine whether these differences between molecules are
functionally significant. In all structures, a short loop region
between helices H and I was not modeled (Fig. 2) because of
poor density, suggesting that this region is disordered. In two
molecules of the structure with 17␣-hydroxyprogesterone and
three molecules of the structure with 17␣-hydroxypregnenolone, several residues between the C and D helices were
also not modeled because of ambiguous electron density.
NOVEMBER 21, 2014 • VOLUME 289 • NUMBER 47

FIGURE 3. Active site of wild type CYP17A1 (orange) bound to abiraterone
(Protein Data Bank code 3RUK) (8) overlaid with the active site of
CYP17A1 A105L (green) bound to abiraterone. Mutation of residue 105
does not affect the orientation of the abiraterone inhibitor (shown in gray
sticks) but reduces the active site volume specifically in the local region of the
substituted side chain (wild type and A105L active site voids in orange and
green mesh, respectively).

Structure of CYP17A1 A105L with Abiraterone—To determine the effects of the A105L mutation alone on enzyme structure, the CYP17A1 A105L structure was determined in complex with the steroidal inhibitor abiraterone and compared with
that of the wild type enzyme containing this same ligand (Protein Data Bank code 3RUK (8)). The 2.65 Å structure of the
mutant enzyme (Table 1) is essentially identical to the wild type
enzyme at the backbone level and in all other respects, save in
the local region of the single site mutation (Fig. 3). The major
difference between wild type CYP17A1 and the A105L mutant
abiraterone structures is that the additional bulk caused by substitution of leucine for alanine projects directly into what is part
of the active site for the wild type enzyme. Reduction in overall
active site volume from 677 Å3 for the wild type enzyme to 642
Å3 for the A105L mutant is due almost entirely to this substitution. This reduction in active site volume does not alter the
orientation of abiraterone or any of its interactions with the
CYP17A1 active site. The steroid still lies with the unsubstituted ␣ face against the I helix with the steroid plane forming a
60° angle from the plane of the heme. The only intermolecular
hydrogen bond, between the 3␤-hydroxyl group of abiraterone
and Asn202, is present in both structures. Thus in this structure
the impact of the A105L mutation appears to be only steric in
nature.
Structure of CYP17A1 A105L with Hydroxylase Substrates—
Structures of the CYP17A1 A105L mutant with the 17␣-hydroxylase substrates progesterone and pregnenolone were
determined at resolutions of 2.80 and 2.50 Å, respectively
(Table 1). In all four molecules of the asymmetric unit of both
hydroxylase substrate complexes, the ligand steroids assume
the same orientation (Fig. 4, A and B). This general orientation
is also almost identical to that previously observed for abiraterone (Fig. 4C), with the ␣-face of the steroid packed against
the I helix and the cyclopentanophenanthrene steroid nucleus
forming a ⬃60° angle from the heme plane. Abiraterone forms
a hydrogen bond to the side chain of Asn202 in the F helix in
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 4. X-ray structures of CYP17A1 A105L with all four physiological substrates demonstrate overall similar orientations, with the steroid nucleus
at an ⬃60° angle with respect to the heme plane and the steroid ␣-face flat against a peptide bond in the I helix. Hydroxylase substrates pregnenolone
(A, green) and progesterone (B, orange) form hydrogen bonds between their respective C3 alcohol and keto substituents and the side chain amide of Asn202,
an orientation termed position 1 and similar to that observed for the steroidal inhibitor abiraterone (C, cyan). The poor 17,20-lyase substrate 17␣-hydroxyprogesterone (D, magenta) is oriented similar to the hydroxylase substrates in position 1 with its C3 keto group also hydrogen bonding to Asn202. However, in
different molecules of the structure with the efficient lyase substrate 17␣-hydroxypregnenolone, this substrate is found either in position 1 with its C3 hydroxyl
hydrogen bonding to Asn202 (E, purple) or in a position closer to the heme which is too distant from Asn202 to allow hydrogen bonding (F, yellow, position 2).
For clarity, in A–F, the brackets only indicate the distances between C17 and iron. Other distances and angles are provided in Table 1. Electron density is shown
as a 2Fo ⫺ Fc ligand omit map contoured at 1.0 . In G, overlays of hydroxylase substrates pregnenolone (green) and progesterone (orange) demonstrate the
similarity of their binding modes, whereas an overlay of 17␣-hydroxypregnenolone in its two observed positions illustrates important differences in hydrogen
bonding (H).

both the wild type structure (8) and in the A105L mutant (Fig.
4C). Abiraterone and pregnenolone are both ⌬5,3-ol steroids.
Thus it is not surprising that the C3-OH of pregnenolone is also
oriented to form a 2.8 ⫾ 0.1 Å (average; Table 1) hydrogen bond
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to the Asn202 side chain (Fig. 4A). The corresponding C3-keto
substituent of progesterone is located to form a hydrogen bond
of similar length (2.7 ⫾ 0.3 Å average) to Asn202 (Fig. 4B).
Although progesterone must be the hydrogen bond acceptor
VOLUME 289 • NUMBER 47 • NOVEMBER 21, 2014
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and the amide nitrogen of Asn202 must be the hydrogen bond
donor, the donor/acceptor relationship is less clear for pregnenolone. The pregnenolone C3 hydroxyl could be donor or
acceptor, and the side chain nitrogen/oxygen could be donor/
acceptor respectively depending on the side chain torsion. As a
result of their similar hydrogen bonding interactions with
Asn202 (distances and angles; Table 1) and similar packing
against the I helix, the distances from C17 that is hydroxylated
to the iron that would compose the catalytic iron (IV) oxo intermediate are essentially identical (4.8 ⫾ 0.1 Å; Table 1) between
the two hydroxylase substrates. Similarly, C16 (hydroxylated
when progesterone is the substrate, but not when pregnenolone
is the substrate) is also essentially same distance from the heme
iron for both substrates (Table 2) but is located at a greater
angle from the iron than C17 (Fig. 4, A and B).
Structure of CYP17A1 A105L with 17,20-Lyase Substrates—
Structures of CYP17A1 A105L co-crystallized with the efficient
lyase substrate 17␣-hydroxypregnenolone and the poor lyase
substrate 17␣-hydroxyprogesterone were determined to resolutions of 3.0 Å and 2.55 Å, respectively (Table 1). In the 17␣hydroxyprogesterone complex, the ligand binds very similarly
in all four molecules of the crystal and very similar to the orientation observed for the hydroxylase substrates (Fig. 4D). The
hydrogen bond between the C3-keto and side chain amide of
Asn202 is maintained with similar distances and angles (Table
1). The substrate position with respect to the I helix and heme
iron (e.g. C17-iron, 5.0 ⫾ 0.1 Å; Table 1) is also consistent with
the hydroxylase substrates, a state that will be referred to as
position 1. In the 17␣-hydroxypregnenolone structure, the general substrate position relative to the I helix is maintained, but
the substrate is observed to occupy distinct positions that vary
by their relative position between Asn202 and the heme. For two
of the molecules of this structure, 17␣-hydroxypregnenolone is
in position 1 as observed for 17␣-hydroxyprogesterone (Fig.
4E), with its C3 alcohol forming a hydrogen bond to Asn202
(Table 1). However, in the other two molecules of this structure,
17␣-hydroxypregnenolone is found farther from Asn202 and
closer to the heme iron. In its closest approach to the iron, a
state referred to as position 2 (Fig. 4F), the substrate C3 alcohol
is much too far removed from Asn202 to participate in even a
weak hydrogen bond (3.8 Å), and the C17-iron distance is
reduced to 4.4 Å. The fourth molecule shows 17␣-hydroxypregnenolone in an intermediate position. The differences in
position are perhaps better illustrated by comparing the electron density associated with ligand and heme for these various
complexes. For 17␣-hydroxypregnenolone in position 1 and all
other CYP17A1 substrates, the substrate electron density is distinct from that of the heme (Fig. 4, A, B, D, and E), whereas for
17␣-hydroxypregnenolone in position 2, closer to the heme, the
substrate electron density is continuous with the heme (Fig.
4F), more similar to that of abiraterone (Fig. 4C). Thus overlays
of the progesterone and pregnenolone complexes illustrate the
high degree of similarity in their binding (Fig. 4G) in a position
and orientation also shared with 17␣-hydroxyprogesterone
(not shown). However, an overlay of the two binding positions
observed for 17␣-hydroxypregnenolone illustrates differences
in the hydrogen binding to Asn202 and a shift toward the heme.
NOVEMBER 21, 2014 • VOLUME 289 • NUMBER 47

FIGURE 5. Probe-occupied cavities for the active sites of CYP17A1 A105L
bound to progesterone (molecule B and D, yellow and blue, respectively)
exemplify the range of volumes among the present structures. Although
abiraterone always exhibits a minimal active site volume similar to that
shown in blue mesh, for substrates slight modifications of backbone and side
chain torsions in the F-G⬘ region and/or at the base of the F and G helices can
result in a significant extension near C19 and/or enlargement of the extension off C3. In a few cases, these cavities extend to the protein surface.

Further Variation in Active Site Activity Topography—The
amino acid side chains surrounding the active site, the observable waters, and the hydrogen bonding of the I helix that the
steroids pack against are not significantly different between
complexes (even when 17␣-hydroxypregnenolone is positioned nearer to the heme) or between molecules in each structure. Very minor differences reflect small changes in torsion
angles or slightly favored rotamers to best fit the density in each
structure. However, in two regions these small differences
result in substantial variation in active site size and topography
(Fig. 5). Rather than being correlated with a particular substrate, this appears to result primarily from the relatively small
differences in the backbone for molecules A and B versus molecules C and D. Like the wild type structure with abiraterone,
the active site cavity extends beyond the C3 substituent, and
this varies somewhat in size, even between molecules of a particular substrate complex, because of slight differences in side
chain torsions. Additionally, several molecules have extensions
from the main active site extending from the region of the
ligand C19 substituent, which can consist of substantial extra
volume as a result of the slight differences in the F-G⬘ loop
backbone and very slight side chain torsions. In a very few molecules, one or both of these active site extensions reach the
protein surface, at the intersection of the F/G⬘ loop, ␤4 –1, and
the first turn of the A helix or between the bases of the F and G
helices, respectively. If expanded by breathing motions or conformational changes in the protein, these channels could play a
role in ligand entry/exit. The cavity over the I helix exiting at the
base of the F and G helices would be exposed to solvent,
whereas the cavity extension exiting in the region of the F/G⬘
loop would be expected to be buried in the membrane.

DISCUSSION
The reactions catalyzed by CYP17A1 have long been of substantial interest because they occur at a key juncture in human
steroidogenesis, controlling the biosynthesis of mineralocorticoids, glucocorticoids, and sex steroid androgens and estrogens. Originally thought to be performed by two different
enzymes, a steroid 17␣-hydroxylase and a 17,20-lyase or -desJOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 6. Combination of structural and functional data supports the following models for CYP17A1 catalysis. A, regioselectivity and substrate selectivity of hydroxylation. Whereas the major binding modes for progesterone and pregnenolone are oriented with C17 directed toward the iron for 17␣hydroxylation (gray sticks, orientation observed in structures), the steroid core of progesterone may also adopt an alternate plane that facilitates C16 hydroxylation (salmon sticks, proposed orientation). The A105L mutation suppresses this alternate orientation, decreasing C16 hydroxylation, increasing C17
hydroxylation, and slightly increasing hydroxylation of C21 on the opposite side of the substrate. Pregnenolone may not adopt this alternate orientation
favoring C16 hydroxylation because its C3 hydroxyl is restrained by a stronger hydrogen bond with Asn202. Gray mesh is CYP17A1 wild type active site cavity.
B, in the current model for substrate selectivity of the lyase reaction, 17␣-hydroxyprogesterone may be a poor 17,20-lyase substrate because of its positioning
in the active site. This substrate is only observed hydrogen bonding to Asn202 such that it is farther away from the iron, and its C17 hydroxyl is predicted to
hydrogen bond with the distal oxygen of the peroxy intermediate, an interaction that is not conducive to the lyase reaction. C, in contrast, 17␣-hydroxypregnenolone may be a more efficient substrate for the lyase reaction because it is observed to move closer to the iron, where studies suggest the C17 hydroxy may
hydrogen bond with the proximal oxygen of the catalytic peroxy intermediate. This position would facilitate nucleophilic attack of the distal oxygen on C20 to
perform the lyase reaction. The well established facilitation of the lyase reaction by b5 is consistent with an allosteric interaction favoring 17␣-hydroxypregnenolone in position 2 versus position 1.

molase, both catalytic functions were later shown to be accomplished by CYP17A1 (47). In part to explain how both reactions
might occur in the single CYP17A1 active site, the concept of a
“bi-lobed” active site was advanced (36), in which the different
lobes would carry out the separate hydroxylase and lyase reactions. Homology models and docking studies suggested that
substrates were likely to orient essentially parallel to the plane
of the heme (32–34). In contrast, the first available structures of
CYP17A1, which were complexes of steroidal inhibitor analogs
of pregnenolone, did not support a bi-lobed cavity and demonstrated ligand orientation more nearly perpendicular to the
heme than parallel (8). However, both of these inhibitors contained nitrogen heterocycles as substituents to the steroid scaffold at C17 and coordinated to the heme iron. In the absence of
further data, subsequent work has been interpreted with differing models of steroid substrate orientation either parallel (46)
or more perpendicular to the heme (8, 24) within the CYP17A1
active site. Herein experimental structures of CYP17A1 with
each of the four substrates clearly demonstrate that steroid substrates adopt a binding orientation generally consistent with
that of the steroidal inhibitors in the original x-ray structures
(Fig. 4).
One possible caveat might be that all of the current structures were obtained in the presence of the A105L mutation.
However, the only structural difference between the wild type
and A105L structures with the common ligand abiraterone was
a steric difference in active site volume as the larger leucine
filled active site space unoccupied by abiraterone (Fig. 3). The
mutation did not alter the orientation of the steroidal inhibitor
in the CYP17A1 active site. The reduction in the excess width of
the active site engendered by the alanine to leucine substitution
is consistent with decreases in Kd for most substrates and
decreases in hydroxylation Km values (Table 2). This evidence
and concordance with functional evidence discussed below
suggests that the A105L mutation does not significantly alter
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the primary orientation of substrate steroids important for C17
hydroxylation.
Thus the structural results herein are first integrated with the
functional hydroxylase data to propose an internally consistent
hypothesis for CYP17A1 hydroxylase selectivities. The orientations observed for CYP17A1 with progesterone or pregnenolone in the current structures are consistent with production of
the major 17␣-hydroxy metabolites observed. In both cases,
C17 is oriented toward the heme iron. The C17␣ hydrogens of
both hydroxylase substrates are located such that they would be
clearly most susceptible to abstraction by the iron (IV) oxo
intermediate in the hydroxylase reaction (Fig. 4, A and B). The
C17 hydrogen is not located directly over the heme iron, but a
few degrees off center, consistent with the moderate reported
kinetic isotope effect for progesterone 17␣-hydroxylation,
interpreted as a bent transition state (46). Wild type and the
A105L mutant have essentially the same kinetic isotope effect
for 17␣-hydroxylation, 4.1 and 3.8, respectively (46), further
supporting the idea that ligand orientation for 17␣-hydroxylation is unperturbed by the mutation.
Combination of the current structural and functional data
suggests a mechanism underlying the generation of minor progesterone metabolites. Depending on the system under study,
wild type CYP17A1 also hydroxylates progesterone to yield
10 –30% (17, 46) of the total product as 16␣-hydroxyprogesterone and has also been reported to produce trace amounts of
21-hydroxyprogesterone (46). The C16 and C21 hydrogens
flank the C17 hydrogen, and the current structure positions
them such that they would be the next most susceptible for
hydrogen abstraction by the iron oxo intermediate (Fig. 6A,
experimental ligand position in gray sticks). In the purified system, wild type CYP17A1 produced 88% of the total progesterone metabolites with hydroxylation at C17, whereas the
remaining 12% was the minor C16-hydroxylated product, and
21-hydroxyprogesterone was not detected. Consistent with
VOLUME 289 • NUMBER 47 • NOVEMBER 21, 2014

CYP17A1/Steroid Substrate Structures
previous reports (17, 46), the A105L mutation decreased the
percentage of 16-hydroxylated product, increased 17-hydroxylated product, and could produce trace amounts of the 21hydroxylated metabolite 11-deoxycorticosterone. Thus the
A105L mutation, whose nearest atom is some 8 –11 Å away
from the site of metabolism, substantially reduces 16-hydroxylation on one side of C17 and slightly increases C21 hydroxylation on the opposite side of C17, suggesting a rotation of the
substrate in the active site (Fig. 6A, proposed minor orientation
in pink sticks).
The present structural information demonstrates that A105L
occludes part of the active site volume adjacent to the B⬘
helix (Fig. 3). This volume is not utilized by progesterone
binding in a mode consistent with 17-hydroxylation. However,
the functional data suggest that the availability of active site
volume near Ala105 correlates with the production of 16␣-hydroxyprogesterone. In the wild type enzyme, progesterone
might take advantage of the cavity space near Ala105 to adopt a
variation of the observed progesterone orientation that preferentially exposes C16 for hydroxylation (Fig. 6A, pink). Because
the steroid nucleus is a relatively rigid body, reduction of volume near Ala105 would be structurally consistent with the proposition that the A105L active site topography disallows such
alternative positioning of progesterone in the CYP17A1 active
site, reducing production of the minor 16␣-hydroxyprogesterone metabolite, increasing the catalytic efficiency of 17␣-hydroxylation, and slightly increasing C21 access to the iron for
hydroxylation as observed experimentally.
Thus it is proposed that in the wild type enzyme, the progesterone long axis can adopt at least two orientations in the wild
type active site (Fig. 6A). The major one would pack directly
against the I helix and hydrogen bond to Asn202 as observed in
the crystal structure, resulting in the major 17␣-hydroxy
metabolite. The minor orientation would be most consistent
with a shift of the long axis of the steroidal core, pivoting about
C17 to move the C3 substituent into the space adjacent to
Ala105 near the B⬘ helix, where it perhaps cannot hydrogen
bond with Asn202. This proposed position for progesterone
would move C16 toward the iron, increasing the likelihood of
abstraction of one of the C16 hydrogens and subsequent
hydroxylation to yield the minor product. This model is coincident with intramolecular kinetic isotope effect studies demonstrating that the A105L mutation affects the transition state
for hydrogen abstraction at C16, with negligible effects on progesterone C17 hydroxylation (46). It is therefore likely that the
proposed alternative positioning is a very modest rotation of
the steroid about C17 that affects the proximity of C16 to the
oxygen of compound I without substantial effects on C17.
Detection of the proposed progesterone minor orientation
would not be likely by x-ray crystallography, especially within
the context of the A105L mutation background. In summary,
the contribution of the A105L mutation to more efficient 17␣hydroxylation appears to be related to the binding of substrates
and doing so in an optimal position for hydrogen abstraction at
the appropriate carbon.
The current structural and functional data also suggest a
potential mechanism for differential regiospecificity between
hydroxylase substrates. Although the wild type active site cavity
NOVEMBER 21, 2014 • VOLUME 289 • NUMBER 47

topography suggests that pregnenolone could adopt a similar
minor orientation resulting in the generation of 16␣-hydroxypregnenolone, no such product is observed experimentally
(16). This could be due to a stronger hydrogen bonding interaction with Asn202 for pregnenolone compared with progesterone. Pregnenolone (and 17␣-hydroxypregnenolone) have a C3
hydroxyl substituent with the ability to serve as either hydrogen
bond donor or acceptor to the Asn202 side chain amide, which
can also serve as donor or acceptor depending on the orientation. These substrates bind more tightly than either of the
corresponding ⌬4,3-keto progesterone-based ligands (Table
2), as reflected by at least a 2-fold decrease in the Kd and
perhaps even more by the 17-hydroxylase Km, which is a full
order of magnitude lower for pregnenolone than its ⌬4,3keto counterpart progesterone. This stronger interaction
with Asn202 could inhibit pregnenolone from adopting the
minor orientation proposed for progesterone and inhibit
pregnenolone 16-hydroxylation.
A second debate in the field of steroidogenesis centers on the
mechanism and substrate selectivity of the lyase reaction.
Human CYP17A1 performs the 17,20-lyase reaction much
more efficiently on 17␣-hydroxypregnenolone to form the
physiologically relevant androgen dehydroepiandrosterone,
with metabolism of 17␣-hydroxyprogesterone to the corresponding 17,20-lyase product androstenedione 50-fold lower
(16, 25), despite similar Kd values (Table 2). However, the current structural results suggest a basis for this selectivity.
Although both lyase substrates can hydrogen bond to Asn202
similar to the hydroxylase substrates, the poor lyase substrate
17␣-hydroxyprogesterone was only observed in this position
(called position 1). In contrast, the favored lyase substrate 17␣hydroxypregnenolone is also observed closer to the heme and
far enough from Asn202 that this hydrogen bond is no longer
present (termed position 2). The potential significance of this
substrate repositioning was investigated by modeling the proposed intermediate for the lyase reaction into both substrate
complexes. The peroxy state (22, 23) was modeled by incorporating the heme-bound oxygenated state observed in P450cam
(48), wherein the proximal oxygen is bound to the iron and the
distal oxygen is oriented toward a portion of the adjacent I helix
with noncanonical hydrogen bonding (Fig. 6, B and C). The
CYP17A1 I helix shows similar noncanonical hydrogen bonding interactions at this position, although a water molecule
observed in this groove for P450cam is not apparent for
CYP17A1. With the iron peroxy modeled in this manner, the
distance between the distal oxygen of the peroxo thought to
perform nucleophilic attack on the substrate C20 position is
similar for both substrate positions (⬃3.2 Å), but the distance
between C17 and the proximal oxygen goes from 3.6 Å in position 1 to 3.0 Å in position 2. As a result, in position 1 (the only
position observed for 17␣-hydroxyprogesterone), the C17
hydroxyl is positioned to best interact with the distal oxygen of
the peroxy intermediate (Fig. 6B). In contrast, position 2
(observed only for 17␣-hydroxypregnenolone) brings the C17
hydroxyl within a similar distance to the proximal oxygen of the
peroxy intermediate (Fig. 6C). Hydrogen bonding of the C17
hydroxyl to the distal oxygen as suggested by position 1 would
tend to promote breakage of the oxygen-oxygen bond, leading
JOURNAL OF BIOLOGICAL CHEMISTRY

32961

CYP17A1/Steroid Substrate Structures
to the generation of compound I and depressing the lyase reaction (24). Hydrogen bonding of the C17 hydroxyl to the proximal oxygen, as suggested by 17␣-hydroxypregnenolone in position 2, would tend to preferentially stabilize the peroxy
intermediate and leave the distal oxygen available to perform
nucleophilic attack on C20 of the substrate, thereby facilitating
the lyase reaction. Thus subtle positioning of the substrate over
the heme-peroxy intermediate, as mediated by the distant
interaction with Asn202, is proposed to modulate substrate
selectivity for the lyase reaction. This hypothesis is consistent
with several orthogonal lines of evidence. First, although the
residue at Asn202 may not be the only factor, the identity of this
residue appears to largely correlate with lyase specificity in various species. For CYP17A1 from human, sheep, cow, and pig,
the residue at position 202 is an asparagine and these proteins
preferentially perform the lyase reaction on the 17␣-hydroxypregnenolone substrate to produce dehydroepiandrosterone.
Conversely hamster, mouse, rat, and guinea pig have a threonine at position 202 and preferentially perform the lyase reaction on 17␣-hydroxyprogesterone, yielding androstendione.
Second, resonance Raman spectroscopy supports differential
hydrogen bonding of the efficient and poor lyase substrates to
the proximal or distal oxygens, respectively, for the ferrous
dioxygen state immediately preceding the peroxy state in the
P450 catalytic cycle (24). Third, resonance Raman studies with
CYP17A1 bound to CO demonstrate that two distinct ironcarbon-oxygen vibrational modes exist for 17␣-hydroxypregnenolone, and only a single mode exists in the presence of
hydroxylase substrates and the poor lyase substrate, 17␣-hydroxyprogesterone (49). Thus the recent functional and current structural evidence converges to strongly support two
binding modes for 17␣-hydroxypregnenolone, one of which is
oriented appropriately to stabilize the peroxo intermediate and
undergo the lyase reaction. Finally, repositioning of 17␣-hydroxypregnenolone lower in the active site to promote the lyase
reaction is consistent with the effects of the A105L mutation,
where filling space in the distal part of the active site cavity
results in a 5-fold increase in kcat with no change in Km.
A third major conundrum with respect to CYP17A1 biochemistry is how the presence of cytochrome b5 promotes the
17,20-lyase reaction to increase androgen production in specific tissues and during human development. Cytochrome b5
binding is not associated with electron delivery to CYP17A1,
but nonetheless increases the 17,20-lyase reaction as much as
10-fold (25). One might suggest that stabilization of the lyase
iron-oxo intermediate might be accomplished if b5 binding
inhibited protonation of the iron-peroxo intermediate. The
peroxo intermediate operative in the lyase reaction must first
be protonated on the distal oxygen, followed by a second protonation and loss of water to yield the iron-oxo compound I
intermediate required for hydroxylation. However, this is
incompatible with the observation that b5 does not reduce the
hydroxylation reaction (25). Alternatively, b5 binding has been
suggested to allosterically alter CYP17A1 conformation and/or
substrate orientation to promote the lyase activity (25), but a
mechanism for this has not been previously elucidated (50).
The current structural results suggest that this might occur by
altering the distribution of 17␣-hydroxypregnenolone in posi-
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tion 1 (not conducive to the lyase reaction) versus position 2
(compatible with productive lyase chemistry). The anionic
Glu48 and Glu49 residues of cytochrome b5 are known to interact with the cationic Arg347, Arg358, and Arg449 CYP17A1 residues based on both mutagenesis and recent solution NMR
binding studies (31, 51). This means that the b5 binding site is
on the opposite side of the heme and 11–21 Å away from the
buried active site. Recently, however, solution NMR results
established that b5 binds differentially to CYP17A1 depending
on whether the hydroxylase substrate pregnenolone or the
lyase substrate 17␣-hydroxypregnenolone is present in the buried CYP17A1 active site (51). Cytochrome b5 binding on the
proximal side of CYP17A1 has been demonstrated to change
the backbone conformations for F helix residues Ile205 and
Ile206 adjacent to Asn202 (52), although information on Asn202
itself is not yet available. The functional and structural data
suggest that communication between the b5 binding site and
the active site could allosterically favor 17␣-hydroxypregnenolone binding in position 2. Optimized positioning of 17␣hydroxypregnenolone for the lyase reaction would be consistent with the observed decrease in the amount of uncoupling
for the lyase reaction when b5 is present (53), increasing the
lyase product generated without substantially altering
CYP17A1 hydroxylase activity, which is already ⬃97% coupled
(53). Although we have been unable to replicate these results,
phosphorylation of CYP17A1 is also reported to facilitate the
lyase reaction (54, 55) and could similarly promote a conformation of CYP17A1 that increases 17␣-hydroxypregnenolone in
position 2 closer to the heme.
In summary, the balance of human mineralocorticoids, glucocorticoids, androgens, and estrogens depends on the interactions of CYP17A1 with its four different steroidal substrates.
Although structural information has previously been lacking,
the current set of x-ray structures establishes that each of these
substrates binds in the CYP17A1 active site with the site(s) of
metabolism oriented toward the heme, the ␣ face packed
against the I helix, and the C3 keto or alcohol substituent
hydrogen bonding to Asn202 in the F helix. Complexes with the
hydroxylase substrates progesterone and pregnenolone demonstrate primary binding modes consistent with production of
the observed 17␣-hydroxy major metabolites, whereas the
structural and functional effects of the A105L mutation suggest
a minor alternate orientation that is not seen in the current
structure but that would be consistent with the 16␣-hydroxylation observed for progesterone but not pregnenolone. Comparison of complexes between the poor lyase substrate 17␣-hydroxyprogesterone and the efficient lyase
substrate 17␣-hydroxypregnenolone reveal that only 17␣-hydroxypregnenolone is also observed positioned closer to the
heme without hydrogen bonding to Asn202. This latter position,
termed position 2, is consistent with spectroscopic evidence
suggesting that 17␣-hydroxypregnenolone hydrogen bonds
differently to the proposed peroxy catalytic intermediate compared with its ⌬4,3keto counterpart, resulting in C-C bond
cleavage only for 17␣-hydroxypregnenolone. Finally, cytochrome b5 binding to CYP17A1 is known to have an allosteric
effect on the active site, which would be consistent with favoring 17␣-hydroxypregnenolone localization nearer the heme in
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position 2 and potentially decreasing nonproductive uncoupling of the catalytic cycle. In aggregate, the set of structures
herein provide a structural basis for the regioselectivity and
substrate specificity of the hydroxylation reaction and the substrate specificity of the lyase reaction, as well as providing
potential mechanism for the allosteric effects of cytochrome b5
on the lyase reaction. Providing such a structural basis for
understanding key reactions at the crossroads of human steroidogenesis should improve our ability to modulate physiological status in diseases ranging from sexual development, fertility, and hormone-responsive breast and prostate cancer, to
immune and stress responses and blood pressure.
Acknowledgments—The University of Kansas Protein Structure Laboratory was supported by National Institutes of Health Grants
RR01778 and GM103420, and the Stanford Synchrotron Radiation
Lightsource was supported by National Institutes of Health Grants
RR00129 and GM103393.
REFERENCES
1. Miller, W. L., and Auchus, R. J. (2011) The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr.
Rev. 32, 81–151
2. Gilep, A. A., Sushko, T. A., and Usanov, S. A. (2011) At the crossroads of
steroid hormone biosynthesis: the role, substrate specificity and evolutionary development of CYP17. Biochim. Biophys. Acta 1814, 200 –209
3. Edwards, B. K., Noone, A. M., Mariotto, A. B., Simard, E. P., Boscoe, F. P.,
Henley, S. J., Jemal, A., Cho, H., Anderson, R. N., Kohler, B. A., Eheman,
C. R., and Ward, E. M. (2014) Annual report to the nation on the status of
cancer, 1975–2010, featuring prevalence of comorbidity and impact on
survival among persons with lung, colorectal, breast, or prostate cancer.
Cancer 120, 1290 –1314
4. Ferraldeschi, R., and de Bono, J. (2013) Agents that target androgen synthesis in castration-resistant prostate cancer. Cancer J. 19, 34 – 42
5. de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L.,
Chi, K. N., Jones, R. J., Goodman, O. B., Jr., Saad, F., Staffurth, J. N., Mainwaring, P., Harland, S., Flaig, T. W., Hutson, T. E., Cheng, T., Patterson, H.,
Hainsworth, J. D., Ryan, C. J., Sternberg, C. N., Ellard, S. L., Fléchon, A.,
Saleh, M., Scholz, M., Efstathiou, E., Zivi, A., Bianchini, D., Loriot, Y.,
Chieffo, N., Kheoh, T., Haqq, C. M., and Scher, H. I. (2011) Abiraterone
and increased survival in metastatic prostate cancer. New Engl. J. Med.
364, 1995–2005
6. Auchus, M. L., and Auchus, R. J. (2012) Human steroid biosynthesis for
the oncologist. J. Investig. Med. 60, 495–503
7. Loriot, Y., Bianchini, D., Ileana, E., Sandhu, S., Patrikidou, A., Pezaro, C.,
Albiges, L., Attard, G., Fizazi, K., De Bono, J. S., and Massard, C. (2013)
Antitumour activity of abiraterone acetate against metastatic castrationresistant prostate cancer progressing after docetaxel and enzalutamide
(MDV3100). Ann. Oncol. 24, 1807–1812
8. DeVore, N. M., and Scott, E. E. (2012) Structures of cytochrome P450
17A1 with prostate cancer drugs abiraterone and TOK-001. Nature 482,
116 –119
9. Pia, A., Vignani, F., Attard, G., Tucci, M., Bironzo, P., Scagliotti, G., Arlt,
W., Terzolo, M., and Berruti, A. (2013) Strategies for managing ACTH
dependent mineralocorticoid excess induced by abiraterone. Cancer
Treat. Rev. 39, 966 –973
10. Attard, G., Reid, A. H., Auchus, R. J., Hughes, B. A., Cassidy, A. M.,
Thompson, E., Oommen, N. B., Folkerd, E., Dowsett, M., Arlt, W., and de
Bono, J. S. (2012) Clinical and biochemical consequences of CYP17A1
inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J. Clin. Endocrinol.
Metab. 97, 507–516
11. Ogo, A., Haji, M., Ohashi, M., and Nawata, H. (1991) Markedly increased
expression of cytochrome P-450 17␣-hydroxylase (P-450c17) mRNA in

NOVEMBER 21, 2014 • VOLUME 289 • NUMBER 47

12.
13.
14.

15.
16.

17.

18.

19.

20.
21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.

32.

adrenocortical adenomas from patients with Cushing’s syndrome. Mol.
Cell Endocrinol. 80, 83– 89
Maitra, A., and Shirwalkar, H. (2003) Congenital adrenal hyperplasia: biochemical and molecular perspectives. Indian J. Exp. Biol. 41, 701–709
Qin, K. N., and Rosenfield, R. L. (1998) Role of cytochrome P450c17 in
polycystic ovary syndrome. Mol. Cell Endocrinol. 145, 111–121
Arlt, W., Martens, J. W., Song, M., Wang, J. T., Auchus, R. J., and Miller,
W. L. (2002) Molecular evolution of adrenarche: Structural and functional
analysis of p450c17 from four primate species. Endocrinology 143,
4665– 4672
Strauss, J. F., 3rd. (2003) Some new thoughts on the pathophysiology and
genetics of polycystic ovary syndrome. Ann. N.Y. Acad. Sci. 997, 42– 48
Swart, P., Swart, A. C., Waterman, M. R., Estabrook, R. W., and Mason, J. I.
(1993) Progesterone 16␣-hydroxylase activity is catalyzed by human cytochrome P450 17␣-hydroxylase. J. Clin. Endocrinol. Metab. 77, 98 –102
Swart, A. C., Storbeck, K. H., and Swart, P. (2010) A single amino acid
residue, Ala 105, confers 16␣-hydroxylase activity to human cytochrome
P450 17␣-hydroxylase/17,20-lyase. J. Steroid Biochem. Mol. Biol. 119,
112–120
Sohl, C. D., and Guengerich, F. P. (2010) Kinetic analysis of the three-step
steroid aromatase reaction of human cytochrome P450 19A1. J. Biol.
Chem. 285, 17734 –17743
Flück, C. E., Miller, W. L., and Auchus, R. J. (2003) The 17,20-lyase activity
of cytochrome p450c17 from human fetal testis favors the delta5 steroidogenic pathway. J. Clin. Endocrinol. Metab. 88, 3762–3766
Guengerich, F. P. (2007) Mechanisms of cytochrome P450 substrate oxidation: MiniReview. J. Biochem. Mol. Toxicol. 21, 163–168
Groves, J. T., McClusky, G. A., White, R. E., and Coon, M. J. (1978) Aliphatic hydroxylation by highly purified liver microsomal cytochrome
P-450. Evidence for a carbon radical intermediate. Biochem. Biophys. Res.
Commun. 81, 154 –160
Akhtar, M., Corina, D., Miller, S., Shyadehi, A. Z., and Wright, J. N. (1994)
Mechanism of the acyl-carbon cleavage and related reactions catalyzed by
multifunctional P-450s: Studies on cytochrome P-450(17)␣. Biochemistry
33, 4410 – 4418
Gregory, M. C., Denisov, I. G., Grinkova, Y. V., Khatri, Y., and Sligar, S. G.
(2013) Kinetic solvent isotope effect in human P450 CYP17A1-mediated
androgen formation: evidence for a reactive peroxoanion intermediate.
J. Am. Chem. Soc. 135, 16245–16247
Gregory, M., Mak, P. J., Sligar, S. G., and Kincaid, J. R. (2013) Differential
hydrogen bonding in human CYP17 dictates hydroxylation versus lyase
chemistry. Angew. Chem. Int. Ed. Engl. 52, 5342–5345
Auchus, R. J., Lee, T. C., and Miller, W. L. (1998) Cytochrome b5 augments
the 17,20-lyase activity of human P450c17 without direct electron transfer. J. Biol. Chem. 273, 3158 –3165
Katagiri, M., Kagawa, N., and Waterman, M. R. (1995) The role of cytochrome b5 in the biosynthesis of androgens by human P450c17. Arch.
Biochem. Biophys. 317, 343–347
Lee-Robichaud, P., Wright, J. N., Akhtar, M. E., and Akhtar, M. (1995)
Modulation of the activity of human 17␣-hydroxylase-17,20-lyase
(CYP17) by cytochrome b5: endocrinological and mechanistic implications. Biochem. J. 308, 901–908
Onoda, M., and Hall, P. F. (1982) Cytochrome b5 stimulates purified testicular microsomal cytochrome P-450 (C21 side-chain cleavage).
Biochem. Biophys. Res. Commun. 108, 454 – 460
Idkowiak, J., Randell, T., Dhir, V., Patel, P., Shackleton, C. H., Taylor, N. F.,
Krone, N., and Arlt, W. (2012) A missense mutation in the human cytochrome b5 gene causes 46, XY disorder of sex development due to true
isolated 17,20-lyase deficiency. J. Clin. Endocrinol. Metab. 97, E465–E475
Kok, R. C., Timmerman, M. A., Wolffenbuttel, K. P., Drop, S. L., and de
Jong, F. H. (2010) Isolated 17,20-lyase deficiency due to the cytochrome b5
mutation W27X. J. Clin. Endocrinol. Metab. 95, 994 –999
Naffin-Olivos, J. L., and Auchus, R. J. (2006) Human cytochrome b5 requires residues E48 and E49 to stimulate the 17,20-lyase activity of cytochrome P450c17. Biochemistry 45, 755–762
Auchus, R. J., and Miller, W. L. (1999) Molecular modeling of human
P450c17 (17␣-hydroxylase/17,20-lyase): insights into reaction mechanisms and effects of mutations. Mol. Endocrinol. 13, 1169 –1182

JOURNAL OF BIOLOGICAL CHEMISTRY

32963

CYP17A1/Steroid Substrate Structures
33. Schappach, A., and Höltje, H. D. (2001) Molecular modelling of 17␣hydroxylase-17,20-lyase. Pharmazie 56, 435– 442
34. Haider, S. M., Patel, J. S., Poojari, C. S., and Neidle, S. (2010) Molecular
modeling on inhibitor complexes and active-site dynamics of cytochrome
P450 C17, a target for prostate cancer therapy. J. Mol. Biol. 400,
1078 –1098
35. Lin, D., Zhang, L. H., Chiao, E., and Miller, W. L. (1994) Modeling and
mutagenesis of the active site of human P450c17. Mol. Endocrinol. 8,
392– 402
36. Laughton, C. A., Neidle, S., Zvelebil, M. J., and Sternberg, M. J. (1990) A
molecular model for the enzyme cytochrome P450(17␣), a major target
for the chemotherapy of prostatic cancer. Biochem. Biophys. Res. Commun. 171, 1160 –1167
37. Kabsch, W. (2010) XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132
38. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser crystallographic software. J. Appl.
Crystallogr. 40, 658 – 674
39. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and
development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486 –501
40. Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols,
N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C.,
Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. (2010) PHENIX: a
comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221
41. Kleywegt, G. J., and Jones, T. A. (1994) Detection, delineation, measurement and display of cavities in macromolecular structures. Acta Crystallogr. D Biol. Crystallogr. 50, 178 –185
42. DeLano, W. L. ( 2012) The PyMOL Molecular Graphics System, version
1.5.0.1, Schroedinger, LLC, New York
43. Sandee, D., and Miller, W. L. (2011) High-yield expression of a catalytically
active membrane-bound protein: human P450 oxidoreductase. Endocrinology 152, 2904 –2908
44. Moon, J. Y., Kang, S. M., Lee, J., Cho, J. Y., Moon, M. H., Jang, I. J., Chung,
B. C., and Choi, M. H. (2013) GC-MS-based quantitative signatures of
cytochrome P450-mediated steroid oxidation induced by rifampicin.
Ther. Drug Monit. 35, 473– 484
45. DeVore, N. M., Smith, B. D., Wang, J. L., Lushington, G. H., and Scott, E. E.

32964 JOURNAL OF BIOLOGICAL CHEMISTRY

46.

47.

48.

49.

50.

51.

52.

53.

54.

55.

(2009) Key residues controlling binding of diverse ligands to human cytochrome P450 2A enzymes. Drug Metab. Dispos. 37, 1319 –1327
Yoshimoto, F. K., Zhou, Y., Peng, H. M., Stidd, D., Yoshimoto, J. A.,
Sharma, K. K., Matthew, S., and Auchus, R. J. (2012) Minor activities and
transition state properties of the human steroid hydroxylases cytochromes P450c17 and P450c21, from reactions observed with deuteriumlabeled substrates. Biochemistry 51, 7064 –7077
Nakajin, S., and Hall, P. F. (1981) Microsomal cytochrome P-450 from
neonatal pig testis. Purification and properties of A C21 steroid side-chain
cleavage system (17␣-hydroxylase-C17,20-lyase). J. Biol. Chem. 256,
3871–3876
Schlichting, I., Berendzen, J., Chu, K., Stock, A. M., Maves, S. A., Benson,
D. E., Sweet, R. M., Ringe, D., Petsko, G. A., and Sligar, S. G. (2000) The
catalytic pathway of cytochrome p450cam at atomic resolution. Science
287, 1615–1622
Mak, P. J., Gregory, M. C., Sligar, S. G., and Kincaid, J. R. (2014) Resonance
Raman spectroscopy reveals that substrate structure selectively impacts
the heme-bound diatomic ligands of CYP17. Biochemistry 53, 90 –100
Akhtar, M. K., Kelly, S. L., and Kaderbhai, M. A. (2005) Cytochrome b5
modulation of 17␣ hydroxylase and 17–20 lyase (CYP17) activities in steroidogenesis. J. Endocrinol. 187, 267–274
Estrada, D. F., Laurence, J. S., and Scott, E. E. (2013) Substrate-modulated
cytochrome P450 17A1 and cytochrome b5 interactions revealed by NMR.
J. Biol. Chem. 288, 17008 –17018
Estrada, D. F., Skinner, A. L., Laurence, J. S., and Scott, E. E. (2014) Human
cytochrome P450 17A1 conformational selection: modulation by ligand
and cytochrome b5. J. Biol. Chem. 289, 14310 –14320
Khatri, Y., Gregory, M. C., Grinkova, Y. V., Denisov, I. G., and Sligar, S. G.
(2014) Active site proton delivery and the lyase activity of human
CYP17A1. Biochem. Biophys. Res. Commun. 443, 179 –184
Zhang, L. H., Rodriguez, H., Ohno, S., and Miller, W. L. (1995) Serine
phosphorylation of human P450c17 increases 17,20-lyase activity: Implications for adrenarche and the polycystic ovary syndrome. Proc. Natl.
Acad. Sci. U.S.A. 92, 10619 –10623
Tee, M. K., and Miller, W. L. (2013) Phosphorylation of human cytochrome P450c17 by p38␣ selectively increases 17,20-lyase activity and
androgen biosynthesis. J. Biol. Chem. 288, 23903–23913

VOLUME 289 • NUMBER 47 • NOVEMBER 21, 2014

